History of cannabis as a medicine: a review AW Zuardi Brazilian Journal of Psychiatry 28, 153-157, 2006 | 1042 | 2006 |
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients MM Bergamaschi, RHC Queiroz, MHN Chagas, DCG De Oliveira, ... Neuropsychopharmacology 36 (6), 1219-1226, 2011 | 989 | 2011 |
Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology S Bhattacharyya, PD Morrison, P Fusar-Poli, R Martin-Santos, ... Neuropsychopharmacology 35 (3), 764-774, 2010 | 887 | 2010 |
Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects AW Zuardi, I Shirakawa, E Finkelfarb, IG Karniol Psychopharmacology 76, 245-250, 1982 | 868 | 1982 |
Safety and side effects of cannabidiol, a Cannabis sativa constituent M Machado Bergamaschi, R Helena Costa Queiroz, A Waldo Zuardi, ... Current drug safety 6 (4), 237-249, 2011 | 761 | 2011 |
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report JAS Crippa, GN Derenusson, TB Ferrari, L Wichert-Ana, FLS Duran, ... Journal of psychopharmacology 25 (1), 121-130, 2011 | 706 | 2011 |
Alcohol Use Disorders Identification Test (AUDIT): An updated systematic review of psychometric properties. C de Meneses-Gaya, AW Zuardi, SR Loureiro, JAS Crippa Psychology & Neuroscience 2 (1), 83, 2009 | 689 | 2009 |
Cannabis and anxiety: a critical review of the evidence JA Crippa, AW Zuardi, R Martín‐Santos, S Bhattacharyya, Z Atakan, ... Human Psychopharmacology: Clinical and Experimental 24 (7), 515-523, 2009 | 669 | 2009 |
Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing P Fusar-Poli, JA Crippa, S Bhattacharyya, SJ Borgwardt, P Allen, ... Archives of general psychiatry 66 (1), 95-105, 2009 | 618 | 2009 |
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug AW Zuardi, JAS Crippa, JEC Hallak, FA Moreira, FS Guimarães Brazilian journal of medical and biological research 39, 421-429, 2006 | 601 | 2006 |
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action AW Zuardi Brazilian Journal of Psychiatry 30, 271-280, 2008 | 579 | 2008 |
Effects of ipsapirone and cannabidiol on human experimental anxiety AW Zuardi, RA Cosme, FG Graeff, FS Guimarães Journal of psychopharmacology 7 (1_suppl), 82-88, 1993 | 464 | 1993 |
Cannabidiol for the treatment of psychosis in Parkinsons disease AW Zuardi, JAS Crippa, JEC Hallak, JP Pinto, MHN Chagas, ... Journal of Psychopharmacology 23 (8), 979-983, 2009 | 456 | 2009 |
Effects of cannabidiol in the treatment of patients with Parkinsons disease: an exploratory double-blind trial MHN Chagas, AW Zuardi, V Tumas, MA Pena-Pereira, ET Sobreira, ... Journal of Psychopharmacology 28 (11), 1088-1098, 2014 | 438 | 2014 |
Antianxiety effect of cannabidiol in the elevated plus-maze FS Guimarães, TM Chiaretti, FG Graeff, AW Zuardi Psychopharmacology 100, 558-559, 1990 | 417 | 1990 |
Antipsychotic effect of cannabidiol. AW Zuardi, SL Morais, FS Guimarães, R Mechoulam The Journal of clinical psychiatry, 1995 | 379 | 1995 |
Effects of cannabidiol (CBD) on regional cerebral blood flow JAS Crippa, AW Zuardi, GEJ Garrido, L Wichert-Ana, R Guarnieri, ... Neuropsychopharmacology 29 (2), 417-426, 2004 | 374 | 2004 |
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the
RG Dos Santos, FL Osório, JAS Crippa, J Riba, AW Zuardi, JEC Hallak Therapeutic advances in psychopharmacology 6 (3), 193-213, 2016 | 370 | 2016 |
Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age JA Crippa, FS Guimarães, AC Campos, AW Zuardi Frontiers in immunology 9, 2009, 2018 | 361 | 2018 |
Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers R Martin-Santos, J a Crippa, A Batalla, S Bhattacharyya, Z Atakan, ... Current pharmaceutical design 18 (32), 4966-4979, 2012 | 321 | 2012 |